Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression.

Roarty K, Pfefferle AD, Creighton CJ, Perou CM, Rosen JM.

Oncogene. 2017 Oct 26;36(43):5958-5968. doi: 10.1038/onc.2017.206. Epub 2017 Jun 26.

2.

Ex Vivo Expanded Adaptive NK Cells Effectively Kill Primary Acute Lymphoblastic Leukemia Cells.

Liu LL, Béziat V, Oei VYS, Pfefferle A, Schaffer M, Lehmann S, Hellström-Lindberg E, Söderhäll S, Heyman M, Grandér D, Malmberg KJ.

Cancer Immunol Res. 2017 Aug;5(8):654-665. doi: 10.1158/2326-6066.CIR-16-0296. Epub 2017 Jun 21.

PMID:
28637877
3.

Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.

Pfefferle AD, Agrawal YN, Koboldt DC, Kanchi KL, Herschkowitz JI, Mardis ER, Rosen JM, Perou CM.

Dis Model Mech. 2016 Jul 1;9(7):749-57. doi: 10.1242/dmm.025239. Epub 2016 May 5.

4.

Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes.

Usary J, Darr DB, Pfefferle AD, Perou CM.

Curr Protoc Pharmacol. 2016 Mar 18;72:14.38.1-11. doi: 10.1002/0471141755.ph1438s72. Review.

5.

Harnessing adaptive natural killer cells in cancer immunotherapy.

Liu LL, Pfefferle A, Yi Sheng VO, Björklund AT, Béziat V, Goodridge JP, Malmberg KJ.

Mol Oncol. 2015 Dec;9(10):1904-17. doi: 10.1016/j.molonc.2015.10.001. Epub 2015 Oct 20. Review.

6.

Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.

Sohlberg E, Pfefferle A, Andersson S, Baumann BC, Hellström-Lindberg E, Malmberg KJ.

Oncotarget. 2015 Oct 27;6(33):34178-90. doi: 10.18632/oncotarget.6213.

7.

Acrylamide in a fried potato dish (rösti) from restaurants in Zurich, Switzerland.

McCombie G, Biedermann M, Biedermann-Brem S, Suter G, Eicher A, Pfefferle A.

Food Addit Contam Part B Surveill. 2016;9(1):21-6. doi: 10.1080/19393210.2015.1102974. Epub 2015 Nov 20.

PMID:
26462849
8.
9.

Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential.

Knezevic J, Pfefferle AD, Petrovic I, Greene SB, Perou CM, Rosen JM.

Oncogene. 2015 Dec 3;34(49):5997-6006. doi: 10.1038/onc.2015.48. Epub 2015 Mar 9.

10.

Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy.

Pfefferle AD, Spike BT, Wahl GM, Perou CM.

Breast Cancer Res Treat. 2015 Jan;149(2):425-37. doi: 10.1007/s10549-014-3262-6. Epub 2015 Jan 10.

11.

Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells.

Wennerberg E, Pfefferle A, Ekblad L, Yoshimoto Y, Kremer V, Kaminskyy VO, Juhlin CC, Höög A, Bodin I, Svjatoha V, Larsson C, Zedenius J, Wennerberg J, Lundqvist A.

Clin Cancer Res. 2014 Nov 15;20(22):5733-44. doi: 10.1158/1078-0432.CCR-14-0291. Epub 2014 Sep 11.

12.

Toso controls encephalitogenic immune responses by dendritic cells and regulatory T cells.

Brenner D, Brüstle A, Lin GH, Lang PA, Duncan GS, Knobbe-Thomsen CB, St Paul M, Reardon C, Tusche MW, Snow B, Hamilton SR, Pfefferle A, Gilani SO, Ohashi PS, Lang KS, Mak TW.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1060-5. doi: 10.1073/pnas.1323166111. Epub 2014 Jan 7.

13.

Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts.

Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR, Torres-Arzayus MI, Brown M, Egan SE, Wahl GM, Rosen JM, Perou CM.

Genome Biol. 2013 Nov 12;14(11):R125. doi: 10.1186/gb-2013-14-11-r125.

14.

c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer.

Nair R, Roden DL, Teo WS, McFarland A, Junankar S, Ye S, Nguyen A, Yang J, Nikolic I, Hui M, Morey A, Shah J, Pfefferle AD, Usary J, Selinger C, Baker LA, Armstrong N, Cowley MJ, Naylor MJ, Ormandy CJ, Lakhani SR, Herschkowitz JI, Perou CM, Kaplan W, O'Toole SA, Swarbrick A.

Oncogene. 2014 Jul 24;33(30):3992-4002. doi: 10.1038/onc.2013.368. Epub 2013 Sep 23.

PMID:
24056965
15.

Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis.

Harrell JC, Pfefferle AD, Zalles N, Prat A, Fan C, Khramtsov A, Olopade OI, Troester MA, Dudley AC, Perou CM.

Clin Exp Metastasis. 2014 Jan;31(1):33-45. doi: 10.1007/s10585-013-9607-4. Epub 2013 Aug 22.

16.

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.

Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL.

Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14372-7. doi: 10.1073/pnas.1303204110. Epub 2013 Aug 12.

17.

Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.

Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL.

Cancer Res. 2013 Jul 1;73(13):4075-85. doi: 10.1158/0008-5472.CAN-12-4579. Epub 2013 Apr 30.

18.

Glutathionylation of UCP2 sensitizes drug resistant leukemia cells to chemotherapeutics.

Pfefferle A, Mailloux RJ, Adjeitey CN, Harper ME.

Biochim Biophys Acta. 2013 Jan;1833(1):80-9. doi: 10.1016/j.bbamcr.2012.10.006. Epub 2012 Oct 12.

19.

Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.

Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, Johnson SM, Combest AJ, Jin J, Zamboni WC, Johnson GL, Perou CM, Sharpless NE.

Clin Cancer Res. 2012 Oct 1;18(19):5290-303. doi: 10.1158/1078-0432.CCR-12-0563. Epub 2012 Aug 7.

20.

Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver.

Wallace MD, Pfefferle AD, Shen L, McNairn AJ, Cerami EG, Fallon BL, Rinaldi VD, Southard TL, Perou CM, Schimenti JC.

Genetics. 2012 Oct;192(2):385-96. doi: 10.1534/genetics.112.142802. Epub 2012 Jul 30.

21.

LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.

Liu W, Monahan KB, Pfefferle AD, Shimamura T, Sorrentino J, Chan KT, Roadcap DW, Ollila DW, Thomas NE, Castrillon DH, Miller CR, Perou CM, Wong KK, Bear JE, Sharpless NE.

Cancer Cell. 2012 Jun 12;21(6):751-64. doi: 10.1016/j.ccr.2012.03.048.

22.

Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation.

Hutti JE, Pfefferle AD, Russell SC, Sircar M, Perou CM, Baldwin AS.

Cancer Res. 2012 Jul 1;72(13):3260-9. doi: 10.1158/0008-5472.CAN-11-4141. Epub 2012 May 2.

23.

A potential role for glucose transporters in the evolution of human brain size.

Fedrigo O, Pfefferle AD, Babbitt CC, Haygood R, Wall CE, Wray GA.

Brain Behav Evol. 2011;78(4):315-26. doi: 10.1159/000329852. Epub 2011 Oct 7.

24.

Comparative expression analysis of the phosphocreatine circuit in extant primates: Implications for human brain evolution.

Pfefferle AD, Warner LR, Wang CW, Nielsen WJ, Babbitt CC, Fedrigo O, Wray GA.

J Hum Evol. 2011 Feb;60(2):205-212. doi: 10.1016/j.jhevol.2010.10.004. Epub 2010 Dec 28.

25.

A pipeline to determine RT-QPCR control genes for evolutionary studies: application to primate gene expression across multiple tissues.

Fedrigo O, Warner LR, Pfefferle AD, Babbitt CC, Cruz-Gordillo P, Wray GA.

PLoS One. 2010 Sep 2;5(9). pii: e12545. doi: 10.1371/journal.pone.0012545.

26.

Both noncoding and protein-coding RNAs contribute to gene expression evolution in the primate brain.

Babbitt CC, Fedrigo O, Pfefferle AD, Boyle AP, Horvath JE, Furey TS, Wray GA.

Genome Biol Evol. 2010 Jan 18;2:67-79. doi: 10.1093/gbe/evq002.

27.

The relationship between ankylosed primary molars and multiple enamel defects.

Rule JT, Zacherl WA, Pfefferle AM.

ASDC J Dent Child. 1972 Jan-Feb;39(1):29-35. No abstract available.

PMID:
4551109

Supplemental Content

Loading ...
Support Center